Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.18 -0.98

Overview

Share price change

24h

Current

Min

11.86

Max

12.54

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

125.5

57.002

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+15.78% upside

Market Stats

By TradingEconomics

Market Cap

269M

2.2B

Previous open

13.16

Previous close

12.18

News Sentiment

By Acuity

100%

0%

324 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2026, 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

11 sie 2026, 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

11 sie 2026, 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

11 sie 2026, 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

11 sie 2026, 23:51 UTC

News

Matthews International Corp names Michael J. Whitehead as CEO, succeeding Joseph C. Bartolacci. Shares are trading higher in after-market hours amid leadership transition optimism.

11 sie 2026, 23:46 UTC

News

Kilroy Realty Corp shares are higher in after-market trading following the departure of CFO Jeffrey Kuehling and the appointment of Eliott Trencher as interim CFO.

11 sie 2026, 23:46 UTC

News

Whirlpool Corp reported Q2 earnings that missed revenue and adjusted EPS expectations. Shares were roughly flat in after-market trading following the results.

11 sie 2026, 23:41 UTC

News

Clean Energy Fuels reported Q2 revenue of $106.4 million, exceeding expectations. The positive outlook for profitability growth boosted shares during after-market hours.

11 sie 2026, 23:41 UTC

News
Correlated Moves

BlackRock is joining Nvidia's $500 billion AI infrastructure initiative, though concerns about funding sustainability have contributed to lower after-market trading for the firm.

11 sie 2026, 23:41 UTC

News

Anterix shares fell in after-market trading despite a fiscal Q1 earnings beat, reporting net income of $240,000 and EPS of $0.01.

11 sie 2026, 23:41 UTC

News
Social Media

H&R Block reported fiscal 2026 revenue of $3.95 billion, exceeding expectations, and raised its dividend by 10%, contributing to a significant after-market increase.

11 sie 2026, 23:36 UTC

News

UBS upgraded Jabil Inc to Buy, maintaining a $430 price target. Shares are trading higher in after-market hours, supported by strong technical indicators.

11 sie 2026, 23:31 UTC

News

Ameresco Inc shares rose in after-market trading following strong Q2 earnings, reporting $515.5 million in revenue and raising full-year adjusted EPS guidance to $1.25.

11 sie 2026, 23:26 UTC

News
Social Media

Oracle Corp partners with Quantinuum to enhance cloud services with quantum computing. Shares are trading higher in after-market hours following the announcement.

11 sie 2026, 23:11 UTC

News
Social Media

General Motors shares declined in after-market hours following the announcement of a $4.5 billion Supplier Inventory Financing Program and plans to sell its battery joint venture stake.

11 sie 2026, 23:11 UTC

News
Social Media

Lumentum Holdings reported fiscal Q4 adjusted EPS of $3.23, exceeding estimates, and provided optimistic Q1 FY27 guidance, driving shares higher in after-market hours.

11 sie 2026, 23:06 UTC

News

Uber Technologies Inc. sold its entire stake in Serve Robotics, raising investor concerns about its delivery strategy. Shares traded lower during after-market hours.

11 sie 2026, 23:06 UTC

News

ATI Inc reported stronger second-quarter results, raising 2026 adjusted EBITDA guidance to $1.135 billion to $1.185 billion. Shares advanced in after-market hours.

11 sie 2026, 23:06 UTC

News

KKR & Co Inc has invested in Crowe Advisory LLC, enhancing service capabilities. Shares are trading higher in after-market hours following the announcement.

11 sie 2026, 23:06 UTC

News

SiTime Corp shares rose in after-market trading following a strong earnings report, highlighting 127% revenue growth and GAAP profitability.

11 sie 2026, 23:06 UTC

News

Blue Owl Capital prices $750 million in Senior Notes due 2036, aiming to repay borrowings. Shares are higher in after-market trading following the announcement.

11 sie 2026, 23:06 UTC

News

UBS initiated coverage on Century Aluminum Co with a Buy rating and a $60 price target, contributing to after-market gains.

11 sie 2026, 23:02 UTC

News

Agree Realty Corp declared a monthly cash dividend of $0.267, a 4.3% increase, contributing to a modest rise in shares during after-market hours.

11 sie 2026, 23:01 UTC

News

Siebert Financial Corp reports Q2 revenue of $31.2 million, up from $14.9 million last year. Shares are trading higher in after-market hours.

11 sie 2026, 23:01 UTC

News

Century Communities has acquired the Harbor Pointe community in Santa Ana. Shares are lower during after-market hours despite this expansion in Southern California.

11 sie 2026, 23:01 UTC

News

PagSeguro Digital shares rose in after-market hours following its Q2 earnings report, which showed a recurring net profit of 576 million reais, exceeding estimates.

11 sie 2026, 23:01 UTC

News
Event

Astronics Corporation reported second-quarter net income of $35.1 million and raised full-year revenue guidance, boosting shares higher in after-market trading.

11 sie 2026, 23:01 UTC

News

Arbor Realty Trust closed an $825 million collateralized loan obligation securitization, enhancing its balance sheet. Shares moved higher during after-market hours.

11 sie 2026, 23:01 UTC

News

Stereotaxis reported second-quarter revenue of $7.67 million, missing estimates and down from last year's $8.90 million. Shares traded roughly flat in after-market hours.

11 sie 2026, 23:01 UTC

News

Darling Ingredients announced a $150 million sale of production tax credits, boosting shares in after-market hours as investors react positively to the deal.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

15.78% upside

12 Months Forecast

Average 14.53 USD  15.78%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat